BEGIN:VCALENDAR
VERSION:2.0
CALSCALE:GREGORIAN
PRODID:iCalendar-Ruby
BEGIN:VEVENT
LAST-MODIFIED:20070621T114503
SEQUENCE:0
CONTACT:enquiries@confsec.co.uk
ORGANIZER:RSC Biological and Medicinal Chemistry Sector
DTEND:20071018T170000
UID:2008-09-06T22:04:46-0400_124917842@socialweb1
DESCRIPTION:CNS drug discovery continues to be one of the key growth areas 
 in modern pharmaceutical research\, often bringing with it particular chall
 enges in the areas of pharmacokinetics\, animal models and translational me
 dicine/clinical predictivity . In addition to more traditional areas of CNS
  investigation e.g. pain relief and treatment for depression\, changes in l
 ifestyle and increasing longevity have opened up new challenges e.g. treatm
 ents for Alzheimer's Disease and Parkinson's\, and for complications associ
 ated with obesity. This one day meeting aims to showcase real case historie
 s and emerging technology as well as have experts address the latest develo
 pments and future prospects in CNS drug discovery. The meeting will be of i
 nterest to all medicinal chemists and other scientists involved in preclini
 cal drug discovery disciplines in the area of CNS disorders.
\n
\n*_Program
 me_*
\n
\n09.15 Registration and Coffee
\n
\nChair: Ian Churcher (GlaxoSmit
 hKline)
\n
\n10.00 Ann Hayes (The Ann Hayes Consultancy Ltd)
\nCNS drug dis
 covery – where are we and what are the prospects for the future?
\n
\n11.
 00 Mark Tricklebank (Eli Lilly)
\nHarnessing preclinical behavioural neuros
 cience for drug discovery
\n
\n11.45 Anne Hersey (GlaxoSmithKline)
\nUse of
  in-silico methods to aid our understanding of CNS penetration
\n
\n12.30 L
 unch
\n
\nChair: Stuart Cameron (Tripos Discovery Research)
\n
\n13.30 Jere
 my Burrows (AstraZeneca\, Sweden)
\nGSK-3 inhibitors for the treatment of A
 lzheimer's Disease
\n
\n14.15 Gavin Whitlock (Pfizer Global R&D)
\nDiscover
 y of PF-184298\, a dual serotonin/noradrenaline reuptake inhibitor
\n
\n15.
 00 Tea
\n
\n15.30 Paul Radcliffe (Organon Laboratories)
\nIdentification an
 d exploration of a novel series of heterocyclic cannabinoid receptor agonis
 ts for the treatment of pain
\n
\n16.15 Gary Tilbrook (CeNeS Limited)
\nCNS
 7056B: an ultra-short acting benzodiazepine
\n
\n17.00 Close of meeting
SUMMARY:New Frontiers in CNS Drug Discovery
DTSTART:20071018T091500
CREATED:20070621T114048
DTSTAMP:20080906T220446
LOCATION:GlaxoSmithKline New Frontiers Science Park 
END:VEVENT
END:VCALENDAR